Medical Cannabis Demand Expected to Grow

According to Arcview Market Research and BDS Analytics, the global spending on cannabis is expected to reach USD 57 Billion by 2027. Of that rather large sum, 33% is expected to be spent on medical cannabis alone. With all the furor for recreational cannabis that has overtaken North America, it is easy to forget the significance of its medical counterpart. With currently only 9 states, and Washington DC., having legalized recreational cannabis and with medical cannabis being legal in 31 states, and Washington DC., there is a lot of potential for the market.

Currently, the largest cultivators for cannabis, be it recreational or medical, are either in the West Coast of the United States or across the Northern border, in Canada. According to growersnetwork, the largest current grower on the West Coast and in the United States is Los Suenos Farms, a 1,428,000 sq. ft. facility in Avondale, Colorado. Los Suenos is a private company and is bound, like all other cultivators, from delivering its product across state lines as cannabis remains a Schedule 1 substance. On the other side of the country, growersnetwork reports that GrowHealthy LLC is the largest cultivator on the East Coast, with a 200,000 sq. ft. facility in Lake Wales, Florida.

Meanwhile, in Canada, The Green Organic Dutchman (OTCQX: TGODF, TSE: TGOD) and Canopy Growth Corp. (NYSE: CGC) are competing to be the largest producers with 620,000 sq. ft. and 598,000 sq. ft, respectively.

A major reason why the East Coast is lagging behind the West in terms of facilities is due to the order of legalization that the United States has followed. In terms of legalizing medical use of cannabis, California did so in 1996; Washington, Oregon and Alaska did so in 1998, before Colorado and Nevada passed medical legalization in 2000. By comparison, Maine was the only state on the East Coast to have passed medical legalization before 2000, doing so in 1999. As such, the West Coast has had a major advantage in terms of how long the market has been active and the size of the markets that have been opened to cannabis companies.

However, the East Coast is catching up. Massachusetts had legalized medical usage in 2012 before New Hampshire did so in 2013 and New York and Maryland followed suit in 2014. Pennsylvania, Ohio and Florida all legalized medical cannabis in 2016.

According to New Frontier Data, via Statista, the Massachusetts market is expected to see approximately USD 1.37 Billion in cannabis sales by 2025, compared to Maine’s USD 432 Million in sales for the same year. As the market expands on the East Coast, demand will grow and the need for flower will surge. This is where AmeriCann Inc. (OTCQB: ACAN) comes in. The Company recently broke ground on a nearly 1 Million sq. ft. facility in Freetown, Massachusetts, just 47 miles from Boston, to be the location for its Massachusetts Medical Cannabis Center (MMCC). It is not only expected to become one of the largest cultivation facilities in the country but also a leader in cultivation technology and lean practices.  The initial phase (Phase 1) will consist of building out a 30,000 sq. ft. facility to engage in cultivation, processing and research, with an agreement already been reached to lease the initial facility to Coastal Compassions, Inc. (CCI). The facility will feature a team of horticultural, big agricultural, lean manufacturing, cannabis cultivation and consumer production as well as manufacturing expertise, according to Tim Keogh’s speech at the groundbreaking.

While cross-state delivery is still prohibited by the Federal government, the upcoming facility will allow AmeriCann to establish a foothold in the large Massachusetts market, before eventually expanding if the Federal prohibition is lifted.

Sponsored Content Release. Click for Full Disclosure

  1. Adam Putz 8 months ago

    Medical Cannabis availability leads to a decreased number of opioid deaths.

  2. Jeanuel D. 8 months ago

    Medical Cannabis is a great addition to treatment plans for veterans with PTSD. #TrusttheGanja

  3. Ingmar M. 8 months ago

    Medical cannabis provides an important ‘new’ set of pharmacologic tools for health care; a lot to be learned to be more specific and precise #CannabinoidScience #MolecularReality -#SharedFacts

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Americann Inc. financial and corporate news dissemination, has been compensated five thousand dollars by axiom group. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: .